Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5323-5328

  Allampallam, Krishnan ^a   Shetty, Vilasini ^a   Hussaini, Seema ^a   Mazzoran, Lucia ^a   Zorat, Francesca ^a   Huang, Raywin ^a   Raza, Azra ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

Bone marrow; Cytokines; MDS; RNA

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; CYTOKINE RECEPTOR; FLT3 LIGAND; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; HUMAN; MYELODYSPLASTIC SYNDROME; PARENCHYMA; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; AGED; BASE SEQUENCE; BONE MARROW; CHILD; CYTOKINES; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033389116     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Resogetti L: The nature and natural history of myelodysplasia. Hematologica 25 (3): 191-204, 1993.
2. Yoshida Y, Stephenson J, Mufti GJ: Myelodysplastic Syndromes: From morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int J Hematol 57(2): 87-97, 1993.
3. Aul C, Gaterman N, Schneider W: Age-related and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82(2): 358-367, 1992.
4. Raza A, Gregory SA, Preisler HD: The myelodysplastic syndromes in 1996: Complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 20(11/12): 881-890, 1996.
5. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S: A paradigm shift in myelodysplastic syndromes. Leukemia 10: 1648-1652, 1996.
6. Clark DM, Lampert IA: Apoptosis is a common histopathological f mding in myelodysplasia: The correlate of ineffective hematopoiesis. Leuk Lymphoma 2: 415-418, 1990.
7. Haffill SJ, Fester ED, Steytler JG: Apoptotic megakaryocyte dysplasia in myelodysplastic syndromes. Hematologic Pathol 6(2): 87-93, 1992.
8. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86(1): 268-276, 1995.
9. Hellstrom-Lindberg E, Kanter-Lewnsohn OA: Morphologic changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with G-C SF and erythropoietin. Leuk Res 21(5): 415-425, 1997.
10. Bogdanovic AD, Tripnac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD: Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 11 (5): 656-659, 1997.
11. Parcharidou A, Raza A, Economopoulos T, Papageorgiou E, Anagnostou D, Papadaki T, Raptis S: Extensive apoptosis of bone marrow cells as evaluated by in the in situ end labelirlg (ISEL) technique may be the basis for ineffective hematopoiesis in patients with myelodysplastic syndromes. Eur J Haematol 62(1): 19-26, 1999.
12. Yoshida Y, Anzai N, Kawabata H: Apoptosis in myelodysplasia: A paradox or paradigm. Leuk Res 19(12): 887-891, 1995.
13. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C, Raza A: Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20(11/12): 891-900, 1996.
14. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Robin E, Rifkin S, Alston D, Hernandez B, Gregory S: Novel insights into the biology of Myelodysplastic Syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 63: 265-278, 1996.
15. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kawiyama R, Hirokawa K: Overexpression of tumor necrosis factor (TNF)- alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11(12): 2049-254, 1997.
16. Winter SS, Hanissian GA, Harville TO, Ware RE. Tumor necrosis factor-alpha suppresses hematopoiesis in children with myelodysplasia. Med Pediatr Oncol 28(1): 69-74, 1997
17. Mundle S, Mativi BY, Ali A, Bagai K, Akhtar A, Gautam U, Venugopal P, Cartlidge J, Qawi H, Shetty V, Gezer S, Hines C, Gregory SA, Robin E, Rifkin S, Shah R, Raza A: Down- regulation of Fas-associated phosphatase-1 (Fap-1) may underline the Fas-mediated apoptotic death of bone marrow cells in myelodysplasia. Proc Am Assoc Cancer Res 39: 582, Abst#3958, 1998.
18. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ: A role for tumor necrosis factor - a, Fas and'Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103(1): 176-188, 1998.
19. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1): 156-159, 1987.
20. Edwards MC, Gibbs RA: Multiplex PCR: advantages, development and applications. Genome Res 3(4): S65-75, 1994.
21. Raza A, Venugopal P, Gezer S, Gregory S, Dong LM, Leurgens S, Mundle SD, Shetty VT, Alvi S, Ali A, Span L, Dar SE, Hines C, Hsu WT, Loew J, Borok RZ, Hernandez B, Robin E, Rifkin S, Alston D, Shah R, Preisler HD: Pilot study of pentoxifylline and Ciprofloxacin with or without dexamethasone produces encouraging results in myelodysplastic syndromes. Acute Leukemias VII: Experimental Approaches and Novel Therapies published by Springer-Verlag Berlin Heideberg, New York, (eds) W. Hiddemann, T. Buchner, B. Wormann, J. Ritter, U. Creutzig, Keating M, Plunkett W, pp42-51, 1998.
22. Reza S, Shetty V, Dar S, Qawi H, Raza A: Tumor necrosis factor alpha levels decrease with anti-cytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 18(10): 871-877, 1998.
23. Nicholls E. Sian, Winter S, Mottram R, Miyan A. Jaleel, Whetton D. Anthony: Flt3 ligand can promote survival and macrophage development without proliferation in myeloid prgenitor cells. Experimental Hematol 27: 663-672, 1999.